ETP-46464 NEW
| Price | $34 | $55 | $89 |
| Package | 2mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: ETP-46464 | CAS No.: 1345675-02-6 |
| Purity: 99.56% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | ETP-46464 |
| Description | ETP-46464 is an effective and specific ATR inhibitor (IC50: 25 nM). |
| In vivo | ETP-46464 (1 μM) exhibits inhibitory effects on the G2/M phase checkpoint induced by ionizing radiation, resulting in cells with micronuclei or completely fragmented nuclei. It significantly enhances the toxicity in p53-deficient cells, particularly under replicative stress conditions like cyclin E overexpression, intensifying the toxicity. At a concentration of 100 nM, ETP-46464 can fully inhibit ATR activity. Furthermore, ETP-46464 inhibits the activity of PI3Kα (IC50: 170 nM), mTOR (IC50: 0.6 nM), and DNA-PKcsmTOR (IC50: 36 nM) proteins. It promotes damage due to replication fork stalling and induces extensive DNA damage in replicating cells. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | Ethanol : < 1 mg/mL (insoluble or slightly soluble) DMSO : 6 mg/mL (12.75 mM) H2O : < 1 mg/mL (insoluble or slightly soluble) |
| Keywords | Inhibitor | ATM/ATR | ETP 46464 | ETP-46464 | ATM and RAD3 related | ETP46464 | Ataxia telangiectasia mutated | mTOR | Mammalian target of Rapamycin | inhibit |
| Inhibitors Related | L-Leucine | Capivasertib | Myricetin | Erucic acid | Sapanisertib | (2S,3R,4S)-4-Hydroxyisoleucine | Duvelisib (R enantiomer) hydrochloride | Isoprenaline hydrochloride | Quercetin | Quercetin Dihydrate | Rapamycin | Apilimod |
| Related Compound Libraries | DNA Damage & Repair Compound Library | Bioactive Compound Library | HIF-1 Signaling Pathway Compound Library | Kinase Inhibitor Library | Anti-Breast Cancer Compound Library | Antioxidant Compound Library | Inhibitor Library | Anti-Prostate Cancer Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY